title: Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit.
abstract: Novel targeted therapy for patients with non-small-cell lung cancer (NSCLC) and oncogenic mutations along with poor performance status (PS) sometimes evokes a "Lazarus" response. Moreover, for critically ill patients with NSCLC and respiratory failure requiring mechanical ventilation (MV) in the intensive care unit (ICU), only a few case reports have demonstrated positive outcomes with targeted therapy. This perspective review describes in detail the most recently published data in order to highlight the findings and the main pitfalls of targeted therapy for patients with NSCLC in the ICU.
authors.affiliation: Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan;; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
authors.forename: Chun-Ru
authors.initials: CR
authors.lastname: Chien
authors.affiliation: Division of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung, Taiwan;; Department of Respiratory Therapy, China Medical University, Taichung, Taiwan.
authors.forename: Hung-Jen
authors.initials: HJ
authors.lastname: Chen
keywords: Non-small-cell lung cancer (NSCLC); acute severity score; oncogenic mutation; targeted therapy